October 6, 2015—For the second time in less than a month, a generic-drug manufacturer under congressional investigation for price increases has announced that it owes 340B covered entities refunds due to overcharges.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)